Modi Anjali, Germain Ellen, Soma Vijaya, Munjal Iona, Rinke Michael L
Jt Comm J Qual Patient Saf. 2018 Oct;44(10):599-604. doi: 10.1016/j.jcjq.2018.03.001. Epub 2018 Jun 13.
Literature is limited on pediatric anti-infective medication errors. There is a pressing need for additional research, as studies suggest high rates of overall pediatric medication errors and known harmful side effect profiles for anti-infective medications with narrow dosing ranges. This study aimed to identify risk factors related to harmful anti-infective medication errors in pediatric patients.
A retrospective chart review of all voluntary error reports involving anti-infective medication errors and pediatric patients (0 to < 22 years old) reported June 2014-December 2015 was conducted. Error reports were generated using the hospital's general error reporting system and a pharmacy-based patient surveillance reporting system and were stratified based on the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Medication Error Index. Harmful errors were compared to nonharmful errors using Fisher's exact test.
Of 338 anti-infective medication-related error reports, 13.6% of voluntarily reported errors reached the patient and 1.5% resulted in harm to the patient and required additional monitoring, interventions, and/or prolonged hospitalization. Antibacterials comprised 93.8% of all error reports, with beta-lactams (63.0%), macrolides (6.5%) and glycopeptides (6.2%) the most common classes. When using Fisher's exact test to compare harmful and nonharmful medication errors, the risk factor significantly associated with harmful errors was anti-infective class (p = 0.001).
Voluntarily reported anti-infective medication errors within the pediatric patient population often reached the patient, and specific anti-infective medications are potentially of higher risk. Further investigation and additional quality and patient safety strategies may be needed for these higher-risk profile medications.
关于儿科抗感染药物用药错误的文献有限。由于研究表明儿科用药错误总体发生率较高,且已知窄治疗窗抗感染药物存在有害副作用,因此迫切需要开展更多研究。本研究旨在确定与儿科患者有害抗感染药物用药错误相关的风险因素。
对2014年6月至2015年12月期间报告的所有涉及抗感染药物用药错误及儿科患者(0至<22岁)的自愿性错误报告进行回顾性病历审查。错误报告通过医院的一般错误报告系统和基于药房的患者监测报告系统生成,并根据国家用药错误报告和预防协调委员会(NCC MERP)用药错误指数进行分层。使用Fisher精确检验比较有害错误和无害错误。
在338份与抗感染药物相关的错误报告中,13.6%的自愿报告错误涉及患者,1.5%导致患者伤害,需要额外监测、干预和/或延长住院时间。抗菌药物占所有错误报告的93.8%,其中β-内酰胺类(63.0%)、大环内酯类(6.5%)和糖肽类(6.2%)最为常见。使用Fisher精确检验比较有害和无害用药错误时,与有害错误显著相关的风险因素是抗感染药物类别(p = 0.001)。
儿科患者群体中自愿报告的抗感染药物用药错误往往涉及患者,特定的抗感染药物潜在风险可能更高。对于这些高风险药物,可能需要进一步调查以及额外的质量和患者安全策略。